Patents by Inventor Klaus Erb
Klaus Erb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969700Abstract: A mixing apparatus containing a drive unit having a drive and a shaft that is pivotable about a pivot axis and is operatively connected to the drive. A pivotable receptacle is arranged on the shaft, where the pivot axis is oriented essentially horizontally, and the pivotable receptacle has a base plate and at least one retainer spaced therefrom, and the pivotable receptacle is configured in such a way that holders for containers can be inserted between the base plate and the at least one retainer in the direction of the pivot axis.Type: GrantFiled: July 24, 2019Date of Patent: April 30, 2024Assignee: TECAN TRADING AGInventors: Dominic Erb, Philipp Riedel, Christian Strebel, Gero Fehr, Klaus Lun, Christoph Karthaus
-
Publication number: 20240000874Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.Type: ApplicationFiled: June 5, 2023Publication date: January 4, 2024Inventors: Philipp MUELLER, Klaus ERB, Patrik ERLMANN, Tobias Friederike NOLDEN, John Edward PARK, Guido WOLLMANN
-
Patent number: 11840566Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: GrantFiled: November 19, 2021Date of Patent: December 12, 2023Assignees: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
-
Patent number: 11707495Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.Type: GrantFiled: January 24, 2020Date of Patent: July 25, 2023Assignees: Boehringer Ingelheim International GmbH, ViraTherapeutics GmbHInventors: Philipp Mueller, Klaus Erb, Patrik Erlmann, Tobias Friederike Nolden, John Edward Park, Guido Wollmann
-
Publication number: 20220177564Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: November 19, 2021Publication date: June 9, 2022Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
-
Publication number: 20220177566Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: November 19, 2021Publication date: June 9, 2022Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
-
Publication number: 20220177565Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: November 19, 2021Publication date: June 9, 2022Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
-
Publication number: 20220153854Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: September 24, 2021Publication date: May 19, 2022Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Klaus Erb, Eric Lorent, John Park, Robert Resnick, Melanie Rieger, Bernd Weigle
-
Patent number: 11208476Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: GrantFiled: March 22, 2021Date of Patent: December 28, 2021Assignees: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
-
Publication number: 20210379130Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CD80 extracellular domain Fc-fusion protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.Type: ApplicationFiled: June 2, 2021Publication date: December 9, 2021Inventors: Philipp MUELLER, Klaus ERB, Patrik ERLMANN, Guido WOLLMANN
-
Publication number: 20210214431Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: March 22, 2021Publication date: July 15, 2021Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernhard Weigle, Klaus Erb
-
Publication number: 20210188965Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: December 9, 2020Publication date: June 24, 2021Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
-
Publication number: 20200237838Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.Type: ApplicationFiled: January 24, 2020Publication date: July 30, 2020Inventors: Philipp MUELLER, Klaus ERB, Patrik ERLMANN, Tobias Friederike NOLDEN, John Edward PARK, Guido WOLLMANN
-
Patent number: 8354418Abstract: The present invention relates to compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.Type: GrantFiled: January 9, 2009Date of Patent: January 15, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Trixi Brandl, Udo Maier, Christoph Hoenke, Anne T. Joergensen, Alexander Pautsch, Steffen Breitfelder, Matthias Grauert, Matthias Hoffmann, Stefan Scheuerer, Klaus Erb, Michael Pieper, Ingo Pragst
-
Patent number: 8334378Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.Type: GrantFiled: February 17, 2010Date of Patent: December 18, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Trixi Brandl, Udo Maier, Matthias Hoffmann, Stefan Scheuerer, Anne T. Joergensen, Alexander Pautsch, Steffen Breitfelder, Matthias Grauert, Christoph Hoenke, Klaus Erb, Michael Pieper, Ingo Pragst
-
Publication number: 20100145041Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.Type: ApplicationFiled: February 17, 2010Publication date: June 10, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Trixi BRANDL, Udo MAIER, Matthias HOFFMANN, Stefan SCHEUERER, Anne T. JOERGENSEN, Alexander PAUTSCH, Steffen BREITFELDER, Matthias GRAUERT, Christoph HOENKE, Klaus ERB, Michael PIEPER, Ingo PRAGST
-
Patent number: 7691868Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.Type: GrantFiled: March 23, 2007Date of Patent: April 6, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Trixi Brandl, Udo Maier, Matthias Hoffmann, Stefan Scheuerer, Anne T. Joergensen, Alexander Pautsch, Steffen Breitfelder, Matthias Grauert, Christoph Hoenke, Klaus Erb, Michael Pieper, Ingo Pragst
-
Publication number: 20090131424Abstract: Disclosed are compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.Type: ApplicationFiled: January 9, 2009Publication date: May 21, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Trixi BRANDL, Udo MAIER, Christoph HOENKE, Anne T. JOERGENSEN, Alexander PAUTSCH, Steffen BREITFELDER, Matthias GRAUERT, Matthias HOFFMANN, Stefan SCHEUERER, Klaus ERB, Michael PIEPER, Ingo PRAGST
-
Patent number: 7517995Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-cyclopentapyrazoles and the use thereof as pharmaceutical compositions.Type: GrantFiled: March 23, 2007Date of Patent: April 14, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Steffen Breitfelder, Udo Maier, Christoph Hoenke, Anne T. Joergensen, Alexander Pautsch, Trixi Brandl, Matthias Grauert, Matthias Hoffmann, Stefan Scheuerer, Klaus Erb, Michael Pieper, Ingo Pragst
-
Publication number: 20090093474Abstract: The present invention relates to new thiazolyl-dihydro-indazoles of general formula (I) wherein the groups R1, R2 and R3 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.Type: ApplicationFiled: November 25, 2008Publication date: April 9, 2009Inventors: Matthias Grauert, Udo Maier, Matthias Hoffmann, Stefan Scheuerer, Anne T. Joergensen, Alexander Pautsch, Trixi Brandl, Christoph Hoenke, Steffen Breitfelder, Klaus Erb, Michael Pieper, Ingo Pragst
